Analysis of Inavolisib Price Trends and Drug Purchase Channels in 2025

Inavolisib (trade name: Itovebi) is a new type of PI3K developed by Roche (Roche) α-selective inhibitors are mainly used to treat hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA mutations. In 2024 October , the US FDA has approved its use in combination with fulvestrant and palbociclib, which has significantly improved progression-free survival and overall survival, becoming another drug with the same target that has received widespread attention after apelvis. With the latest research data released at the 2025ASCO conference, its efficacy advantages have been further confirmed, and inalise has quickly attracted attention in the global market.

Currently, Inalise has been officially launched in the United States under the trade nameItovebi. According to public quotations, its price in the US market is very expensive: 9mgThe price per box (28tablets) is as high as about 24420USD, which is about RMB 17yuan, and the price of 3mg specification is also over 12,000USD. Since there is no generic version yet, patients around the world can only choose original drugs at this stage, and the price pressure is great. Especially for patients undergoing long-term maintenance treatment, the economic burden cannot be underestimated.

For patients in mainland China, since inalise has not been approved for marketing in China and has not yet been included in the scope of medical insurance reimbursement, it cannot be purchased in domestic hospitals or pharmacies. If medication is needed, it can only be obtained through formal cross-border drug purchase channels, such as overseas authorized pharmacies, international medical referral platforms or qualified import service agencies. In addition, some patients in the United States can obtain fee reductions through patient assistance programs (such asCopay Assistance Program), but such benefits are not yet available to Chinese patients.

Overall, as an innovative targeted drug, the clinical value of inaliset is gradually being recognized globally, but the high price and limited accessibility are still the main obstacles to current promotion. For domestic patients, while waiting for the official introduction, they can discuss with professional oncologists how to try overseas medication, and pay attention to the compliance and safety of drug sources, transportation and use to avoid falling into the trap of illegal drug purchase. If it can be approved for marketing in China and included in medical insurance in the future, the affordability and accessibility of its clinical application will be greatly improved.

Reference materials:https://www.drugs.com/